why choose us

First received: January 24, 2023

Clinical Trial: Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Study Status: Completed

Recruit Status: RECRUITING

Condition: Anatomic Stage II Breast Cancer AJCC v8

Study Type: INTERVENTIONAL


Official Title: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial

Brief Summary: This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer.FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer.PET and CT are imaging techniques that make detailed, computerized pictures of areas inside the…

Read more